|
IQVIA™ Real-World Insights Bibliography
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
|
| Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens
Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore,
Aida Aydemir, Irene Bezemer & Meritxell Sabidó
|
| Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;
b The Alfred Hospital, Melbourne, VIC, Australia;
c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland;
e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany;
f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;
g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland;
h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;
i Department of Clinical Medicine, University of Bergen, Bergen, Norway;
j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
l Bordeaux PharmacoEpi (BPE), Universit?e de Bordeaux, Bordeaux, France;
m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA;
n Global Epidemiology, IQVIA, Amsterdam, The Netherlands;
o Merck Healthcare KGaA, Darmstadt, Germany"
|
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Population Based Study, |
|
 |
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| A real-world, observational study of erenumab for migraine prevention in Canadian patients
|
| Author(s): Werner J Becker 1, Sian Spacey 2, Elizabeth Leroux 3, Rose Giammarco 4, Jonathan Gladstone 5, Suzanne Christie 6, Arash Akaberi 7, G Sarah Power 8, Jagdeep K Minhas 9, Johanna Mancini 7, Driss Rochdi 10, Ayca Filiz 10, Natacha Bastien 10 |
| Affiliations(s): 1Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
2Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada.
3Brunswick Medical Center, Montreal, Quebec, Canada.
4Hamilton Headache Clinic, Hamilton, Ontario, Canada.
5Gladstone Headache Clinic, Toronto, Ontario, Canada.
6Ottawa Headache Centre Inc., Ottawa, Ontario, Canada.
7IQVIA Solutions Canada Inc., Montreal, Quebec, Canada.
8IQVIA Solutions Canada Inc., Mississauga, Ontario, Canada.
9IQVIA Solutions Canada Inc., Ottawa, Ontario, Canada.
10Novartis Canada, Dorval, Quebec, Canada. |
Publication(s): Headache. 2022 Apr;62(4):522-529. doi: 10.1111/head.14291. Epub 2022 Apr 10. PMID: 35403223.
|
| Document Type(s): Article, |
| Countries: Canada, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2022 |
|
L:
A: |
English
Observational study, |
|
|
| |
| |
| The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a
|
| Author(s): Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group |
| Affiliations(s): IQVIA Netherlands, Real World Evidence, Netherlands
b
Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands
c
Medical University of Graz, Graz, Austria
d
Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany
e
St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands |
Publication(s): eNeurologicalSci,
Volume 28,
2022,
100409,
ISSN 2405-6502,
https://doi.org/10.1016/j.ensci.2022.100409.
(https://www.sciencedirect.com/science/article/pii/S2405650222000181)
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, Netherlands , Slovakia, |
| Click here for the abstract |
C:
Y: |
Drug safety, Drug Utlization Study, Neurological disorders,
2022 |
|
L:
A: |
English
Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study, |
|
|
| |
| |
| Nutritional status and use of health resources after the implementation of an enteral nutrition program by PEG probe for neurological patients with home hospitalization
|
| Author(s): Blanco Ramos B, Lopez Garcia B, Gómez Bellvert N.
|
| Affiliations(s): Hospital General Universitario de Elda (Alicante). Carretera Elda-Sax SN. 03600
|
Publication(s): Nutr Hosp
. 2022 Jun 24;39(3):489-498. doi: 10.20960/nh.03813.
|
| Document Type(s): Article, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Neurological disorders, Nutritional Disorders,
2022 |
|
L:
A: |
Spanish
Clinical setting: hospital, Cost benefit, Observational study, Population Based Study, Quality of life, |
|
|
| |
| |
| Real picture of patients with Charcot-Marie-Tooth disease in Japan: IQVIA Claims Database |
| Author(s): Yuki Kado 1, Yuya Tamai 1, Seok-Won Kim 1, Sven Demiya 1 (rwesheorj 1) |
| Affiliations(s): 1) Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan |
Publication(s): ISPOR
|
| Document Type(s): Conference, Poster, Presentation, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2022 |
|
L:
A: |
English
Database Study, |
|
|
| |
| |
| Database study on background information and first-line drug treatment of patients with early-onset Alzheimer's disease |
| Author(s): Shingo Wada 1, Ryosuke Miyagawa 2, Ai Inada 2, Yugo Namiya 2, Komei Iwasaki 2, Ryohei Kobayashi 2, Kaiwei Yan 1 (rwesheorj 1) |
| Affiliations(s): 1) IQVIA Solutions Japan K.K.
2) IQVIA Services Japan K.K. |
Publication(s): The 27th Annual Meeting of the Japanese Society for Pharmacoepidemiology
|
| Document Type(s): Conference, Oral presentation, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2022 |
|
L:
A: |
Japanese
Database Study, |
|
|
| |
| |
| Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. |
| Author(s): Alberto Esquenazi 1, Ganesh Bavikatte 2, Daniel S Bandari 3, Wolfgang H Jost 4 5, Michael C Munin 6, Simon Fuk Tan Tang 7, Joan Largent 8, Aubrey Manack Adams 9, Aleksej Zuzek 9, Gerard E Francisco 10 |
| Affiliations(s): 1MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA.
2The Walton Centre, Liverpool, UK.
3Multiple Sclerosis Center of California, Laguna Hills, CA, USA.
4Department of Neurology, University of Freiburg, Freiburg im Breisgau, Germany.
5Parkinson-Klinik Ortenau, Wolfach, Germany.
6Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
7Department of Physical Medicine and Rehabilitation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
8IQVIA Real-World Evidence Solutions, Cambridge, MA, USA.
9Allergan, An AbbVie company, Irvine, CA, USA.
10University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA. |
Publication(s): PMID: 33151636 DOI: 10.1002/pmrj.12517
|
| Document Type(s): Article, |
| Countries: |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2021 |
|
L:
A: |
English
Epidemiological study, Observational study, |
|
|
| |
| |
| Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy |
| Author(s): Udeh-Momoh CT, Watermeyer T, Price G, de Jager Loots CA, Reglinska-Matveyev N, Ropacki M, Ketter N, Fogle M, Raghavan N, Arrighi M, Brashear R, Di J, Baker S, Giannakopoulou P, Robb C, Bassil D, Cohn M, McLellan-Young H, Crispin J, Lakey K, Lisa C, Chowdary Seemulamoodi Y, Kafetsouli D, Perera D, Car J, Majeed A, Ward H, Ritchie K, Perneczky R, Kivipelto M, Scott D, Bracoud L, Saad Z, Novak G, Ritchie CW, Middleton L |
| Affiliations(s): Imperial College London |
Publication(s): BMJ Open
|
| Document Type(s): Article, |
| Countries: UK, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2021 |
|
L:
A: |
English
Epidemiological study, Observational study, |
|
|
| |
| |
| Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
|
| Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
|
| Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
|
Publication(s): ECTRIMS 2021, Digital, 13-15 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Sweden, |
| Click here for the abstract |
C:
Y: |
Drug Utlization Study, Neurological disorders,
2021 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
 1 of 23 
|
|
